Skip to main content
. 2021 Jan 26;16:147–158. doi: 10.2147/COPD.S272711

Figure 1.

Figure 1

Rcn3 expression in lung tissues from COPD patients. A total of 70 specimens were divided into COPD group and Control group according to the pulmonary function test and pathological changes of emphysema. (A) Photomicrography of pulmonary parenchyma stained with H&E (upper panels). Bar size: 100 μm; IHC assays of Rcn3 from COPD group lungs and Control group lungs (low and high magnifications, lower panels). Bar size: 100 μm; (B) The MLI analysis of H&E stained lung sections (82.78 ± 9.417 μm vs.104.8 ± 5.789 μm, n = 21 in Control group and n = 34 in COPD group, p<0.05); (C) Quantification of the mean optical density of Rcn3 expression in the lung tissues according to the Rcn3 IHC assays (3 random views, 100× amplification for one subject, n = 11–12 per group, p<0.05); (D) Qualitative PCR analyses of the mRNA expressions of Rcn3 and GRP78; the data were normalized to the GAPDH content and were analyzed by the 2−ΔΔCt method relative to the Control group; n = 6 in Control group and n = 10 in COPD group; (E) The protein levels of Rcn3 and GRP78 were examined by Western blot analysis and the ratios to Actin presented by bar graph; n = 6 in Control group and n = 10 in COPD group. Data presented as mean ± SEM; *p<0.05 versus the Control group.